Strategic Funding The Lundquist Institute holds substantial diversified funding, including multi-million grants (notably a $9M CIRM grant and a $1.5M gun violence research grant) and ongoing partnerships, indicating a solid financing runway to support collaborative research projects and sponsored studies with external partners.

Clinical Translation Network With a bedside to bench to bedside translational model, 150+ principal investigators and 600+ active studies including 130 clinical trials annually, there are frequent opportunities to co-develop and commercialize solutions that move quickly from discovery to patient care, appealing to industry partners seeking rapid translational pathways.

Strategic Partnerships Affiliations with UCLA's David Geffen School of Medicine and Harbor-UCLA Medical Center create a prestigious collaboration hub ideal for co-development, access to clinical cohorts, and joint grant opportunities, making partnership pitches more compelling for pharma, biotech, and device companies.

Specialized Capabilities Recent launches such as the SPRINT Core stem cell resource and emphasis on translational genomics, immunology, cancer, and advanced therapeutics highlight distinctive capabilities that can be leveraged for contract research, regulatory-ready studies, and shared-resource access for partners pursuing regenerative medicine and precision health.

Impact and Reach Community health programs serving over 60,000 underserved women and children monthly demonstrate strong impact potential and a value proposition for corporate social responsibility initiatives, patient-centered outcomes programs, and co-funded access programs aligned with health equity goals.